Country: Canada
Language: English
Source: Health Canada
LATANOPROST
BAUSCH & LOMB INC
S01EE01
LATANOPROST
50MCG
SOLUTION
LATANOPROST 50MCG
OPHTHALMIC
2.5ML
Prescription
PROSTAGLANDIN ANALOGS
Active ingredient group (AIG) number: 0132916002; AHFS:
APPROVED
2013-04-02
PRODUCT MONOGRAPH PR BL LATANOPROST Latanoprost Ophthalmic Solution 50 mcg/mL PROSTAGLANDIN F2Α ANALOGUE BAUSCH & LOMB INCORPORATED DATE OF REVISION: 1400 North Goodman Street June 30, 2022 Rochester NY, USA 14609 Imported and Distributed by: BAUSCH + LOMB CORPORATION 520 Applewood Crescent Vaughan, Ontario L4K 4B4 Control #: 260462 _Pr_ _BL LATANOPROST Product Monograph _ _Page 2 of 28_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION.............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS....................................................................................................... 3 WARNINGS AND PRECAUTIONS ...................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 6 DRUG INTERACTIONS ....................................................................................................... 7 DOSAGE AND ADMINISTRATION ..................................................................................... 7 OVERDOSAGE..................................................................................................................... 8 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 9 STORAGE AND STABILITY ...............................................................................................10 DOSAGE FORMS, COMPOSITION AND PACKAGING .....................................................10 PART II: SCIENTIFIC INFORMATION ............................................................................. 11 PHARMACEUTICAL INFORMATION................................................................................11 CLINICAL TRIALS ......................... Read the complete document